Compare ALGM & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGM | TGTX |
|---|---|---|
| Founded | 1990 | 1993 |
| Country | United States | United States |
| Employees | 4250 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 8.5B |
| IPO Year | 2007 | 2008 |
| Metric | ALGM | TGTX |
|---|---|---|
| Price | $45.98 | $55.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $44.27 | ★ $49.80 |
| AVG Volume (30 Days) | ★ 3.2M | 2.1M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.49 | ★ 1746.67 |
| EPS | N/A | ★ 0.12 |
| Revenue | ★ $890,096,000.00 | $2,785,000.00 |
| Revenue This Year | $24.20 | $49.08 |
| Revenue Next Year | $17.94 | $26.69 |
| P/E Ratio | ★ N/A | $462.50 |
| Revenue Growth | ★ 22.77 | N/A |
| 52 Week Low | $22.41 | $25.37 |
| 52 Week High | $71.77 | $59.30 |
| Indicator | ALGM | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 56.49 |
| Support Level | $42.24 | $28.57 |
| Resistance Level | $52.90 | $58.34 |
| Average True Range (ATR) | 3.23 | 2.50 |
| MACD | -0.93 | -0.68 |
| Stochastic Oscillator | 11.11 | 47.57 |
Allegro Microsystems Inc is a designer, developer, fabless manufacturer, and marketer of sensor ICs and application-specific analog power ICs for automotive and industrial markets. Its Sensor IC allows customers to precisely measure motion, speed, position, and current, and Power ICs include high-temperature and high-voltage capable motor drivers, power management, and LED driver ICs. Its products are divided into three categories: SENSE, which includes Current Sensors, Switches, and Latches, and Interface ICs among others; REGULATE, which includes Regulators, ClearPower Modules, and LED Drivers; and DRIVE, which includes BLDC Drivers, Brush DC, and others. Product-wise, the firm derives the majority of its revenue from sales of Magnetic sensors.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.